{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:09:30Z","timestamp":1788307770773,"version":"build-2803163510"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Although influenza vaccination has been associated with Guillain-Barr\u00e9 syndrome (GBS), the findings among studies of older adult populations are inconsistent.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the risk of GBS after influenza vaccination among older adults.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study incorporated a self-controlled case series design. Days 1 to 7, days 1 to 14, and days 1 to 42 after influenza vaccination were identified as risk intervals; days 8 to 180, days 15 to 180, and days 43 to 180 comprised the corresponding control interval. Population-based data were obtained from Taiwan\u2019s National Health Insurance research database between January 1, 2003, and December 31, 2017. Data were analyzed from November 1, 2021, through February 28, 2022. Adults 65 years or older who developed GBS within 180 days after influenza vaccination were enrolled.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Government-funded seasonal influenza vaccination.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Onset of GBS during risk intervals after influenza vaccination compared with control intervals using Poisson regression to calculate incidence rate ratio (IRR).<\/jats:p><\/jats:sec>Results<\/jats:title>Of 13\u202f482\u202f122 adults aged 65 years or older who received an influenza vaccination, 374 were hospitalized for GBS. The mean (SD) age of the study population was 75.0\u2009(6.1) years; 215 (57.5%) were men and 159 (42.5%) were women. In terms of comorbidities, 33 adults (8.8%) had cancer and 4 (1.1%) had autoimmune diseases. The IRRs for GBS during days 1 to 7, days 1 to 14, and days 1 to 42 were 0.95 (95% CI, 0.55-1.61; P<\/jats:italic>\u2009=\u2009.84), 0.87 (95% CI, 0.58-1.29; P<\/jats:italic>\u2009=\u2009.48), and 0.92 (95% CI, 0.72-1.17; P<\/jats:italic>\u2009=\u2009.49), respectively. No results showed statistical significance. Similarly, no significant differences in IRRs were noted for the overall risk interval (ie, days 1-42) in subgroup analyses pertaining to different age groups (65-74 years [0.93 (95% CI, 0.66-1.31)], 75-84 years [0.85 (95% CI, 0.58-1.26)], and \u226585 years [1.10 (95% CI, 0.57-2.11)]), sex (men, 0.97 [95% CI, 0.71-1.33; P<\/jats:italic>\u2009=\u2009.87]; women, 0.85 [95% CI, 0.58-1.23; P<\/jats:italic>\u2009=\u2009.39]), Charlson Comorbidity Index (1.03 [95% CI, 0.77-1.38; P<\/jats:italic>\u2009=\u2009.84]), or comorbidities (cancer, 0.68 [95% CI, 0.28-1.64; P<\/jats:italic>\u2009=\u2009.39]; autoimmune disease, 1.10 [95% CI, 0.11-10.53; P<\/jats:italic>\u2009=\u2009.94]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest that influenza vaccination did not increase the risk of GBS among adults aged 65 years or older in Taiwan regardless of postvaccination period or underlying characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.32571","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:04:07Z","timestamp":1663772647000},"page":"e2232571","source":"Crossref","is-referenced-by-count":12,"title":["Risk of Guillain-Barr\u00e9 Syndrome Among Older Adults Receiving Influenza Vaccine in Taiwan"],"prefix":"10.1001","volume":"5","author":[{"given":"Cheng-Chang","family":"Yen","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Che","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hwa","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"Health Management Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"College of Management, I-Shou University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tung","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Big Data Analytics and Statistics, Department of Medical Research & Development, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"},{"name":"Department of Health Care Management, College of Management, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chia","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Long Term Care, College of Health and Nursing, National Quemoy University, Kinmen County, Taiwan"},{"name":"Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"4","key":"zoi220926r1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barr\u00e9 syndrome.","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"issue":"2","key":"zoi220926r2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis.","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"10045","key":"zoi220926r3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"zoi220926r4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis.","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"zoi220926r5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study.","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"key":"zoi220926r6","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1093\/infdis\/175.Supplement_1.S151","article-title":"Assessment of Guillain-Barr\u00e9 syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance.","volume":"175","author":"Prevots","year":"1997","journal-title":"J Infect Dis"},{"issue":"2","key":"zoi220926r7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977.","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi220926r8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","article-title":"An epidemiologic and clinical evaluation of Guillain-Barr\u00e9 syndrome reported in association with the administration of swine influenza vaccines.","volume":"119","author":"Langmuir","year":"1984","journal-title":"Am J Epidemiol"},{"issue":"20","key":"zoi220926r9","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain-Barr\u00e9 syndrome following influenza vaccination.","volume":"292","author":"Haber","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"zoi220926r10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barr\u00e9 syndrome, influenza, and influenza vaccination: the epidemiologic evidence.","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"25","key":"zoi220926r11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barr\u00e9 syndrome and the 1992-1993 and 1993-1994 influenza vaccines.","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi220926r12","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","article-title":"Guillain-Barr\u00e9 syndrome after influenza vaccination in adults: a population-based study.","volume":"166","author":"Juurlink","year":"2006","journal-title":"Arch Intern Med"},{"issue":"5","key":"zoi220926r13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10654-013-9797-8","article-title":"Risk of Guillain-Barr\u00e9 syndrome after 2010-2011 influenza vaccination.","volume":"28","author":"Galeotti","year":"2013","journal-title":"Eur J Epidemiol"},{"issue":"31","key":"zoi220926r14","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barr\u00e9 syndrome and influenza vaccines: a meta-analysis.","volume":"33","author":"Mart\u00edn Arias","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"zoi220926r15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1982.03330060038030","article-title":"Guillain-Barr\u00e9 syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination.","volume":"248","author":"Kaplan","year":"1982","journal-title":"JAMA"},{"issue":"12","key":"zoi220926r16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/archinte.166.12.1301","article-title":"No association between immunization and Guillain-Barr\u00e9 syndrome in the United Kingdom, 1992 to 2000.","volume":"166","author":"Hughes","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi220926r17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi220926r18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations.","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi220926r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067185","article-title":"Guillain-Barr\u00e9 syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011.","volume":"8","author":"Greene","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"zoi220926r20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/pds.v23.5","article-title":"Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barr\u00e9 syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.","volume":"23","author":"Kawai","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"zoi220926r21","doi-asserted-by":"publisher","first-page":"e2168","DOI":"10.1212\/WNL.0000000000009180","article-title":"Seasonal influenza vaccine and Guillain-Barr\u00e9 syndrome: a self-controlled case series study.","volume":"94","author":"Grave","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"zoi220926r22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/oxfordjournals.aje.a116479","article-title":"Confounding in studies of adverse reactions to vaccines.","volume":"136","author":"Fine","year":"1992","journal-title":"Am J Epidemiol"},{"issue":"10","key":"zoi220926r23","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Tutorial in biostatistics: the self-controlled case series method.","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"zoi220926r24","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs.","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"zoi220926r25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2022.2020108","article-title":"Self-controlled case series design in vaccine safety: a systematic review.","volume":"21","author":"Nie","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"zoi220926r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068373","article-title":"Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.","volume":"376","author":"Li","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"zoi220926r27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan\u2019s new national health insurance program: genesis and experience so far.","volume":"22","author":"Cheng","year":"2003","journal-title":"Health Aff (Millwood)"},{"issue":"20","key":"zoi220926r28","first-page":"252","article-title":"The overview of government-funded influenza vaccination program during influenza season 2011-2012.","volume":"29","author":"Yang","year":"2013","journal-title":"Taiwan Epidemiol Bull"},{"key":"zoi220926r29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP","article-title":"Taiwan\u2019s National Health Insurance Research Database: past and future.","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"5","key":"zoi220926r30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"zoi220926r31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/brain\/90.1.31","article-title":"Peripheral neuropathy of sensorimotor type associated with malignant disease.","volume":"90","author":"Croft","year":"1967","journal-title":"Brain"},{"issue":"3","key":"zoi220926r32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF00314591","article-title":"Peripheral neuropathies and lymphoma without monoclonal gammopathy: a new classification.","volume":"237","author":"Vital","year":"1990","journal-title":"J Neurol"},{"issue":"3","key":"zoi220926r33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00415-004-0317-3","article-title":"Risk of cancer in patients with Guillain-Barr\u00e9 syndrome (GBS). A population-based study.","volume":"251","author":"Vigliani","year":"2004","journal-title":"J Neurol"},{"issue":"3","key":"zoi220926r34","first-page":"88","article-title":"Coexistence of Guillain-Barr\u00e9 syndrome and Beh\u00e7et\u2019s disease.","volume":"31","author":"Shugaiv","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"25","key":"zoi220926r35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011160","article-title":"Systemic lupus erythematosus with Guillian-Barre syndrome: a case report and literature review.","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"zoi220926r36","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3389\/fimmu.2019.01600","article-title":"Neuro-Sj\u00f6gren: peripheral neuropathy with limb weakness in Sj\u00f6gren\u2019s syndrome.","volume":"10","author":"Seeliger","year":"2019","journal-title":"Front Immunol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796566\/yen_2022_oi_220926_1663173111.05468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:04:12Z","timestamp":1663772652000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32571","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}